Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.05), Fidelity Earnings reports.
MBRX traded up $0.01 on Wednesday, reaching $1.22. 785,948 shares of the stock were exchanged, compared to its average volume of 2,600,803. Moleculin Biotech has a fifty-two week low of $0.78 and a fifty-two week high of $3.15. The stock has a market cap of $41.95 million, a P/E ratio of -2.39 and a beta of 2.26.
MBRX has been the subject of several research analyst reports. Maxim Group reiterated a “buy” rating and set a $3.00 target price on shares of Moleculin Biotech in a research report on Wednesday, February 20th. ValuEngine cut Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, Zacks Investment Research cut Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 14th.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Further Reading: Why do commodities matter?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.